Skip to main content

Table 1 Change in HDL-c and HDL subclass in breast cancer patients

From: Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?

Study

Patient enrolled

High Density Lipoproteins

[134]

N = 48 early-stage cancerous breast tumour patients

N = 40 non-cancerous breast tumour patients

HDL-c in breast cancer patients vs. non-cancerous patients

[135]

N = 83 breast cancer patients (Stage I-IV)

N = 83 healthy patients

HDL-c in Stage IV breast cancer patients vs. healthy patients

[136]

N = 58 breast cancer patients

N = 105 healthy patients

No change in HDL-c vs. healthy patients

[132]

N = 30 breast cancer patients

N = 30 healthy patients

HDL-c, HDL2 and HDL3 vs. healthy patients, an effect more pronounced for HDL-2 (-41%) than HDL-3 (-8%)

[131]

N = 56 postmenopausal breast cancer patients (Stage II-IV)

N = 44 healthy patients

HDL-c, HDL2 and HDL3 vs. healthy patients

Furthermore, advancement of disease affects lipid profile where,

HDL-c in Stage IV breast cancer patients vs. Stage II breast cancer patients

[137]

N = 90 breast cancer patients

N = 103 healthy patients

HDL-c in breast cancer patients vs. healthy patients

[138]

N = 100 breast cancer patients (Stage I-IV)

N = 50 healthy patients

No change in HDL-c in breast cancer patients vs. healthy patients

[139]

N = 17 postmenopausal breast cancer patients

N = 30 postmenopausal healthy patients

No change in HDL-c in breast cancer patients vs. healthy patients

[128]

N = 125 breast cancer patients (Stage I -IV)

N = 70 healthy patients

HDL-c breast cancer patients vs. healthy patients

[140]

N = 100 pre- and postmenopausal breast cancer patients

N = 100 healthy patients

No change in HDL-c in breast cancer patients vs. healthy patients

[127]

N = 120 breast cancer patients

N = 60 healthy patient

No change in HDL-c vs. healthy patients

[141]

N = 60 pre- and postmenopausal breast cancer patients

N = 60 healthy patients

No change in HDL-c vs. healthy patients

[142]

N = 249 early stage breast cancer patients

N = 154 healthy patients

HDL-c in breast cancer patients ≤ 50 years old vs. healthy patients

HDL-c in breast cancer patients ≥ 50 years old vs. healthy patients

[133]

N = 56 breast cancer patients (Stage I-II)

No healthy patients included as controls

Large HDL subfractions associated with breast tumours expressing the progesterone receptor

[143]

N = 150 breast cancer patients

N = 75 healthy patients

Unchanged HDL-c vs. healthy patients

[144]

N = 1054 breast cancer patients

N = 2483 healthy patients

HDL-c in breast cancer patients < 60 years old vs. healthy patients

Unchanged HDL-c in breast cancer patients > 60 years old vs. healthy patients

  1. HDL-c High-density lipoprotein-cholesterol, vs. Versus